In the ever-evolving landscape of healthcare investing, the question of which stocks to buy in 2026 is a complex one, especially when considering the contrasting fortunes of Biogen and Novo Nordisk. While both companies operate within the healthcare sector, their strategies, market positions, and growth trajectories couldn't be more different. This article delves into the factors that make each of these stocks an intriguing investment opportunity, and why, in my opinion, the choice between them is not an easy one.
Biogen: A Turnaround Story
Massachusetts-based Biogen is a company in transition. Once a stalwart of the MS (Multiple Sclerosis) market, it is now diversifying its portfolio to include treatments for Alzheimer's, spinal muscular atrophy, and other rare neurological conditions. The company's recent acquisition of Apellis Pharmaceuticals for $5.6 billion has added two promising drugs to its pipeline, Empaveli and Syfovre, which are expected to generate significant revenue growth in the coming years.
What makes Biogen particularly fascinating is its ability to navigate the challenges of an aging population and the increasing demand for specialized treatments. The company's focus on rare diseases, such as Friedreich's ataxia and ALS (Amyotrophic Lateral Sclerosis), positions it well to capitalize on the growing interest in personalized medicine. Moreover, the recent setback with the FDA's extended review period for Leqembi's subcutaneous formulation is a minor hiccup in the grand scheme of things. The drug's approval for IV dosing in over 50 regulatory agencies provides a solid foundation for future growth.
In my opinion, Biogen's stock is well-priced, trading at just under 22 times earnings. The company's diverse pipeline, combined with its strong balance sheet and profitable operations, makes it an attractive investment for those seeking a turnaround story. However, the risk of generic competition for its older blockbuster drugs remains a concern, and the company's ability to maintain its market share in the face of increasing competition will be a key factor in its future success.
Novo Nordisk: A Growth Machine
Novo Nordisk, based in Denmark, is a powerhouse in the markets for diabetes and obesity treatments. The company's GLP-1 agonists, such as Ozempic and Wegovy, have driven significant revenue growth over the past few years. The recent approval of Wegovy in pill form has further fueled demand, and the company's ability to expand manufacturing capacity to meet this demand is a testament to its operational prowess.
What makes Novo Nordisk particularly fascinating is its focus on metabolic health. The company's GLP-1 therapies are not only effective in treating diabetes and obesity, but they also have the potential to reduce the risk of major cardiovascular events and treat chronic kidney disease. This clinical versatility makes these drugs a must-have for insurance providers and healthcare systems, strengthening Novo Nordisk's long-term competitive moat.
In my opinion, Novo Nordisk's stock is trading at just under 11 times earnings, which is a compelling value proposition. The company's strong growth profile, combined with its above-average dividend yield, makes it an attractive investment for those seeking a growth machine. However, the risk of competition from other GLP-1 manufacturers, such as Eli Lilly's Zepbound, remains a concern, and the company's ability to maintain its market share in the face of increasing competition will be a key factor in its future success.
The Choice is Not Easy
The choice between Biogen and Novo Nordisk is not an easy one. Both companies have compelling investment cases, and the decision ultimately comes down to an investor's risk tolerance and investment goals. Biogen's turnaround story and well-priced stock make it an attractive investment for those seeking a value-oriented play, while Novo Nordisk's growth machine and strong dividend yield make it an attractive investment for those seeking a growth-oriented play.
In my opinion, if you're looking for a stock that offers a balance of growth and value, then Novo Nordisk is probably the better buy right now. However, if you're willing to take on more risk for the potential of higher returns, then Biogen's turnaround story and diverse pipeline make it an attractive investment opportunity. Ultimately, the choice is yours, and I encourage you to do your own research and make an informed decision based on your individual circumstances and investment goals.
